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n PLoS Medicine’s launch issue in 
2004, we declared that we would not 
be part of “the cycle of dependency 
that has formed between journals and 
the pharmaceutical industry” (DOI: 
10.1371/journal.pmed.0010022). We 
set out three policies aimed at breaking 
this cycle. First, we would not publish 
adverts for drugs and devices. Second, 
we would not beneﬁ  t from exclusive 
reprint sales to drug companies, 
since our open access license would 
let readers make unlimited copies 
themselves. Third, we would decline 
to publish studies aimed purely at 
increasing a drug’s market share. 
We adopted these policies out of a 
concern that medical journals have 
allowed their interests to become 
too closely aligned with those of 
the marketing departments of drug 
companies. The public response to our 
position has, for the most part, been 
very positive—PLoS Medicine was even 
cited as a “hopeful example” of how 
the medical profession can disentangle 
from industry (Lancet 367: 202). 
And in a recent policy paper in PLoS 
Medicine, Fugh-Berman and colleagues 
argued that other medical journals 
should follow our example and ban 
adverts for drugs and devices (DOI: 
10.1371/journal.pmed.0030130).   
The idea of such a ban has, 
not surprisingly, angered some 
representatives of the pharmaceutical 
industry, which gets a return of 
investment of US$5 for every dollar 
it spends on advertising to doctors 
(http:⁄⁄www.rxpromoroi.org/rapp/
index.html). John Kamp, executive 
director of the Coalition for Healthcare 
Communication, a group of advertising 
agencies and public relations ﬁ  rms 
representing the pharmaceutical 
industry, called Fugh-Berman and 
colleagues’ suggestion a “goofy idea” 
(MMM 23 June 2006). He also said 
that “PLoS Medicine needs to take a 
basic course in the First Amendment 
[the right of free speech in the US 
Constitution].”
Drug companies regularly cry “free 
speech” whenever anyone suggests 
that their promotional efforts should 
be curtailed. Billy Tauzin, president 
of the Pharmaceutical Research 
Manufacturers of America, went so 
far as to suggest that such curtailment 
would be a “human rights abuse” 
(www.mediaweek.com/mw/search/
article_display.jsp?vnu_content_
id=1001002068). This is nonsense. 
Drug advertising is often misleading 
(Ann Intern Med 116: 912–919), 
and it can potentially distort clinical 
practice (Circulation 99: 2055–2057). 
The need to prevent another Vioxx 
tragedy, in which the “drug marketing 
got well ahead of the science” (DOI: 
10.1371/journal.pmed.0030145), 
requires us all to think carefully about 
the net effect upon society of drug 
adverts. Public health must always come 
before industry’s unfettered “rights.” 
Our recent theme issue on disease 
mongering (http:⁄⁄collections.plos.
org/diseasemongering-2006.php) has 
provoked what we believe is a useful 
debate about when marketing comes 
before science.
Alongside the growing public 
scrutiny of drug advertising in journals, 
there is also increasing questioning 
of the way in which journals own the 
copyright on research articles and 
then make huge proﬁ  ts by exclusively 
selling reprints to industry. Such 
proﬁ  ts have the potential to inﬂ  uence 
editorial decisions, and our second 
policy is thus aimed at minimizing this 
potential conﬂ  ict of interest. A recent 
investigative report in The Wall Street 
Journal (May 15th), which examined 
“the New England Journal’s role in the 
Vioxx debacle,” gave an indication of 
the sums of money that change hands 
between journals and drug companies 
in this exclusive reprint trade. The New 
England Journal of Medicine sold 929,400 
reprints of the “Vioxx trial,” more than 
one for every doctor in the US, mostly 
to Merck (the manufacturer of Vioxx), 
bringing in between US$697,000 and 
US$836,000 for the Journal. 
No one questions, however, that 
industry has great expertise in clinical 
research. It has funded many of the 
trials that led to the greatest medical 
breakthroughs (such as the ISIS-II 
study [Lancet 2: 349–360]), and it 
holds the keys to the development of 
many more lifesaving interventions, 
including those aimed at the most 
neglected diseases (DOI: 10.1371/
journal.pmed.0020302). Why then 
did we adopt the third of our policies? 
Our aim was to ensure that we publish 
only those industry-funded studies 
that have important public health 
implications, such as those showing 
under-use of aspirin (DOI: 10.1371/
journal.pmed.0020353) and statins 
(DOI: 10.1371/journal.pmed.0020123) 
for the prevention of cardiovascular 
disease. However, “some studies funded 
by industry have been more helpful to 
marketing than to advancing clinical 
care,” said Patrick Vallance, PLoS 
Medicine editorial board member, 
in his testimony to the UK House of 
Commons Health Committee enquiry 
on the pharmaceutical industry. 
In an interview with PLoS Medicine, 
Vallance said that journals have “got 
to distinguish between science and 
marketing.” He also said that journal 
editors must surely base their decisions 
about whether to publish a study on its 
quality and not on its funding source.
Vallance recently left academia 
to head drug discovery at 
GlaxoSmithKline and we debated 
whether it would represent too much 
of a conﬂ  ict to have an “industry 
insider” in the journal’s ranks. Our 
decision to keep him on our editorial 
board (recognizing his expertise and 
experience) signals our continuing 
PLoS Medicine and the Pharmaceutical Industry
The PLoS Medicine Editors
Citation: The PLoS Medicine Editors (2006) PLoS 
Medicine and the pharmaceutical industry. PLoS Med 
3(7): e329. DOI: 10.1371/journal.pmed.0030329
DOI: 10.1371/journal.pmed.0030329
Copyright: © 2006 The PLoS Medicine Editors. This 
is an open-access article distributed under the 
terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited.
E-mail: medicine_editors@plos.org
“Journals have got to 
distinguish between 
science and marketing.”PLoS Medicine  |  www.plosmedicine.org 0940
interest to work constructively, 
but not unquestioningly, with the 
pharmaceutical industry, within the 
policies of our journal. 
So although we have attracted 
criticism (The Times’ science 
correspondent Mark Henderson, 
for example, said that the “outright 
cynicism” shown by the disease 
mongering theme issue towards 
drug companies can “blind us to the 
beneﬁ  ts” that their products can bring 
[15 April 2005]), we would argue that 
stimulating debate on all issues relating 
to health is one of the jobs of a medical 
journal. A medical journal that accepts 
without question any one position 
serves society’s needs very poorly.
Vallance has spoken about the steps 
that doctors and drug companies 
must both take to ensure a more 
professional, less-conﬂ  icted interaction 
and about the huge beneﬁ  ts to society 
when academia and industry work 
collaboratively. “Interaction between 
academic clinicians and industry,” he 
told the House of Commons, “should 
be open, transparent and appropriately 
recognized by both sides.” We agree, 
and would extend this to saying that 
academic medical journals and industry 
should adopt a similarly “open and 
transparent” relationship.  
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